

YOU ARE INVITED

Gilead Sciences invites you to a ZYDELIG[®] (idelalisib) educational event

Zydelig (idelalisib) Patient Case Study Review

ZYDELIG is FDA approved for 3 indications

Meeting Overview

- Review key details of FDA-approved ZYDELIG Prescribing Information
- Present design of key trials, efficacy profile, and safety profile
- Learn more about dosing and dose modifications

No CME credit is offered

Presented by:

THOMAS KIPPS, MD
PROFESSOR OF MEDICINE
UNIVERSITY OF CALIFORNIA SAN DIEGO

Date:

Saturday, September 26, 2015
1:00 PM PST

Location:

Hyatt Regency Sacramento
Regency Ballroom
1209 L Street
Sacramento, CA 95814

Registration:

Please RSVP or e-mail by
09/23/2015 to:

Steven Shapiro (760) 390-1423 or via email to: steven.shapiro@gilead.com

Please be aware that if you are a licensed US physician, any meal associated with this program is reportable under the Federal Open Payments/Sunshine Act. Gilead policy and the PhRMA Code on Interactions with Healthcare Professionals limit attendance at this promotional educational program to healthcare professionals. Accordingly, attendance by guests is not appropriate and cannot be accommodated.

Please see accompanying full Prescribing Information, including **BOXED WARNING**.



©2015 Gilead Sciences, Inc. All rights reserved. ZYDP0165 06/2015
ZYDELIG, ZYDELIG logo, GILEAD and the GILEAD logo are trademarks
of Gilead Sciences, Inc., or its related companies.

